TOPICS

Tag: Tretinoin

A Split-face, Controlled Study to Assess the Compatibility of Tretinoin 0.05% Acne Lotion with Facial Foundation Makeup

J Clin Aesthet Dermatol. 2020;13(10) by Neal Bhatia, MD; Leon H. Kircik MD; Ava Shamban, MD; Varsha Bhatt, PhD; Radhakrishnan Pillai, PhD; and Eric Guenin, PharmD, PhD, MPH Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Kircik is with Indiana University School of Medicine in Indianapolis, IN, Physicians Skin Care, PLLC,

CONTINUE READING »

Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population

by Sharleen St. Surin-Lord, MD; Todd E. Schlesinger, MD, FAAD; and Eric Guenin, PharmD, PhD, MPH Dr. St. Surin-Lord is with Visage Dermatology and Aesthetics Center in Largo, Maryland. Dr. Schlesinger is with the Clinical Research Center of the Carolinas in Charleston, South Carolina. Dr. Guenin is with Ortho Dermatologics in Bridgewater, New Jersey. FUNDING: Ortho

CONTINUE READING »

Absence of Degradation of Tretinoin When Benzoyl Peroxide is Combined with an Optimized Formulation of Tretinoin Gel (0.05%)

James Q. Del Rosso, DO, Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada; Radhakrishnan Pillai, PhD, Associate Director Project Management, Dow Pharmaceutical Sciences Inc., Petaluma, California; Robert Moore, PhD, Associate Principal Scientist, Dow Pharmaceutical Sciences Inc., Petaluma, California Disclosure: Dr. Del Rosso is a consultant, speaker, and researcher for Coria/Valeant, Allergan, Galderma, Graceway,

CONTINUE READING »

The Use of Sodium Sulfacetamide 10%-Sulfur 5% Emollient Foam in the Treatment of Acne Vulgaris

James Q. Del Rosso, DO, FAOCD, Valley Hospital Medical Center, Las Vegas, Nevada Abstract Acne vulgaris is the most common disorder encountered in ambulatory clinical practice comprising 11.3 percent of office visits to dermatologists in 2005.[1] By comparison, eczematous dermatoses, psoriasis, and skin cancer accounted for 6.2, 3.5, and 10 percent of office visits, respectively.[1]

CONTINUE READING »